Slide 1: Thyrocare - The Trust. The Truth.
Thyrocare The Trust. The Truth. May 10, 2021 The National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Dear Sirs, The Bombay Stock Exchange Ltd Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001 Sub: Presentation on Annual Results for the year
Slide 2: Thyrocare Technologies Limited Presentation
Thyrocare Technologies Limited Presentation – 08.05.2021
Slide 3: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 4: Key Highlights
Key Highlights eee V, Ss | YTOCA The Trust. The Truth.
Slide 5: Revenue, EBITDA Margins, PAT Margins
Revenue EBITDA Margins PAT Margins ` 474 Cr ↑19% normalized ` 176 Cr normalized 37% ` 120 Cr 25% Investigations Novid Samples COVID RTPCR Free Cash Available ` 109 Cr Performed Processed Processed 9.18 Crore 1.58 Crore 10.4 Lac
Slide 6: Pathology revenue revived significantly after Q1
Pathology revenue revived significantly after Q1 Yearly Revenue • Annual growth @ 18.6% (in crore) • Quarterly growth @ 48.6% (YOY) / Non (COVID) @ 30% 118.3 - • Quarterly growth @ 5.3% (Sequentially) 200.5 195.4 • Wellness revenue constitutes 45% of the total Non COVID revenue for the year. 195.9 1
Slide 7: Increase in COVID volume but with stringent price regulations
Increase in COVID volume but with stringent price regulations COVID Q1 Q2 Q3 Q4 Revenue (INR Cr) 23.12 47.65 27.34 20.20 Samples 84,466 2,76,442 2,92,321 3,91,209 Per Sample Revenue 2740 1730 940 520 • Performed 3.91 lac COVID RTPCR tests in Q4 (highest since inception). • Total 10.44 lac COVID RTPC
Slide 8: Recovered and sustained EBITDA margin in spite of Q1 COVID impact
Recovered and sustained EBITDA margin in spite of Q1 COVID impact Particulars Year ended Year ended 31 March 31 March • EBITDA margins impacted due to sharp fall in 2021 (Audited) 2020 (Audited) revenue in Q1 due to COVID lockdown. Revenue from operations 474.27 400.00 Less: Expenses Cost of materia
Slide 9: Radiology revenue revived significantly despite COVID
Radiology revenue revived significantly despite COVID Centrewise Revenue (INR Cr) FYE2021 Centrewise Scans FYE2021 Yearly Revenue Navi Mumbai 3.0 Navi Mumbai 2,652 (in crore) Delhi 2.4 Delhi 2,922 Hyderabad 2.9 Hyderabad 2,496 Prabhadevi 3.1 Prabhadevi 2,758 Aurangabad 1.5 Aurangabad 1,033 31.5 18.5
Slide 10: Breakeven at EBITDA in spite of Q1 COVID impact
Breakeven at EBITDA in spite of Q1 COVID impact Particulars Year ended Year ended 31 March 31 March • Breakeven at EBITDA despite operations severally 2021 2020 impacted due to complete closure of some centers Revenue from operations 20.41 34.09 Less: Expenses in Q1 due to COVID lockdown. Cost of ma
Slide 11: Consolidated financials of the group is not significantly impacted
Consolidated financials of the group is not significantly impacted Particulars Year ended Year ended • EBITDA margins of group were impacted due to sharp 31 March 31 March 2021 2020 fall in revenue in Q1 due to COVID lockdown. Revenue from operations 494.62 433.20 Less: Expenses • Recovery of both p
Slide 12: Thyrocare network at a glance
1500+ 280+ 60000+ 20000+ 20-24 HOURS EMPLOYEES DISTRICTS TOUCH POINTS PARTNERS AVERAGE SAMPLE PROCESSING TIME